How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

552 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. Antiviral treatment for preventing postherpetic neuralgia. (PubMed)

famciclovir. There was no significant difference between the oral acyclovir and control groups on the incidence of PHN four months (risk ratio (RR), 0.75; 95% CI 0.51 to 1.11; P = 0.15) or six months (RR 1.05, 95% CI 0.87 to 1.27; P = 0.62) after the onset of the acute herpetic rash. There was some evidence for a reduction in the incidence of pain four weeks after the onset of rash. In the trial of famciclovir versus placebo, neither 500 mg and 750 mg doses of famciclovir reduced the incidence of herpetic (...) neuralgia significantly.Oral acyclovir did not reduce the incidence of PHN significantly. There is insufficient evidence from randomised controlled trials to determine whether other antiviral treatments prevent PHN. Additional well-designed, randomised controlled trials of famciclovir or other new antiviral agents, with a greater number of participants are needed. Future trials should pay more attention to the severity of pain and quality of life of participants, and should be conducted among different

Full Text available with Trip Pro

2009 Cochrane database of systematic reviews (Online)

342. A Randomized Double-Blind Control-Comparison Crossover Trial of Oral Glutamine to Suppress Frequently Recurrent Herpes Labialis

), cidofovir (intravenous), or foscarnet (intravenous). Suppressive therapy with oral acyclovir, valacyclovir or famciclovir or with topical antivirals 4 weeks prior to enrollment or during the study is not permitted. Use of oral acyclovir or valacyclovir or famciclovir or topical antiviral ointments or creams for the treatment of herpes labialis outbreaks during the study is permitted AFTER the outbreak has been documented by the study team.. Evidence of active herpes labialis reactivation at the time

2009 Clinical Trials

343. Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

, but are not limited to, interferon agents (alpha-, beta- or gamma-interferons), thymosin, IL-12, or other putative systemic immunomodulators. Subject has a history of or clinical signs/symptoms of hepatic decompensation such as ascites, variceal bleeding, hepatic encephalopathy, or spontaneous bacterial peritonitis. Subject has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir (e.g., for recurrent herpes virus infections, etc). Prolonged use means episodic treatment

2009 Clinical Trials

344. Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy

within 7 days prior to study entry or during study period Scheduled administration of any live virus vaccine or inactivated vaccine at or between study entry and the Week 12 visit Participation in an investigational drug study within the last 30 days prior to study entry Use of immunosuppressive therapy. More information can be found in the protocol. Any chronic suppressive antiviral therapy with activity against herpes viruses, including but not limited to acyclovir, famciclovir, valacyclovir

2009 Clinical Trials

345. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. (PubMed)

in the past 24h >or=3 on a 0-10 rating scale initiated 7 days of treatment with famciclovir in combination with 28 days of treatment with either controlled-release (CR) oxycodone, gabapentin, or placebo. Subjects were evaluated for adverse effects of treatment, acute pain, and health-related quality of life. The results showed that CR-oxycodone and gabapentin were generally safe and were associated with adverse events that reflect well-known effects of these medications. Discontinuing participation

2009 Pain Controlled trial quality: uncertain

346. Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)

the preceding two years. Please refer to Appendix 3. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. Please refer to Appendix 1. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00804622 Locations

2008 Clinical Trials

347. Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. Other protocol-defined inclusion/exclusion criteria may

2008 Clinical Trials

348. Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrence and Viral Shedding

, transdermal hormonal contraceptives, IUD (intrauterine device), diaphragm or cervical cap. Willing and able to provide written informed consent, undergo clinical evaluations, and take study drug as directed Exclusion Criteria: History of symptomatic genital herpes, lesions or symptoms consistent with genital herpes, or recurrent undiagnosed symptoms consistent with genital herpes. Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir. Planned open label use of acyclovir (...) , valacyclovir, ganciclovir, valganciclovir, famciclovir, cidofovir, or foscarnet for oral herpes or other herpes viral infections. Medical history of seizures Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl AST (aspartate aminotransferase) or ALT (alanine aminotransferase) over 5 times uper limit of normal History of thrombotic microangiopathy For women, pregnancy as confirmed by a urine or serum pregnancy test. Any other condition which, in the opinion of the principal investigator

2008 Clinical Trials

349. GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women

(Focus HerpeSelect >3.4) At least one prior occurrence of GUD 18-50 years of age Exclusion Criteria: Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir Prior hypersensitivity &/or allergic reaction to acyclovir Use of probenicid Current use, or use within past 28 days, of an investigational agent Currently pregnant or nursing Currently plan to become pregnant during next 3 months Any condition that will interfere with successful completion of study procedures Contacts

2008 Clinical Trials

350. Prednisolone Priming Study in Patients With Chronic Hepatitis B

acyclovir or famciclovir (e.g., for recurrent herpes virus infections). History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP) levels. A history of treated malignancy other than HCC is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding 3 years. One or more known primary or secondary causes

2008 Clinical Trials

351. Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

participating in this study. All other treatments for hepatitis B, including commercially available treatments indicated for conditions other than chronic hepatitis B that are being investigated to treat or may have activity against HBV (e.g., ribavirin, famciclovir, ganciclovir, etc.) Prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with these agents for periods exceeding 10 days every 3 months, or chronic suppressive therapy. Systemic immunomodulators of any type. Systemic

2008 Clinical Trials

352. A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

a history of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatic hydrothorax, hepatopulmonary syndrome or spontaneous bacterial peritonitis. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases

2008 Clinical Trials

353. A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

positive with DNA levels ≥ 1 x 10(5) copies/mL within 30 days of baseline. Patient has ALT levels which are in the range of 2 x ULN and < 10 X ULN Patient who has not a history of ascites, variceal hemorrhage or hepatic encephalopathy. Exclusion Criteria Patient is currently receiving antiviral or corticosteroid therapy. Patients previously treated with lamivudine, adefovir, entecavir, telbivudine, clevudine, lobucavir, famciclovir or any other investigational nucleoside for HBV infection. Previous

2008 Clinical Trials

354. The Effect of Famciclovir on Delayed Facial Paralysis After Acoustic Tumor Resection. (PubMed)

The Effect of Famciclovir on Delayed Facial Paralysis After Acoustic Tumor Resection. To determine the efficacy of prophylactic famciclovir to significantly reduce the percentage of patients experiencing postoperative delayed facial paresis.Prospective evaluation of facial nerve grade for two groups (treated and untreated) with famciclovir before and after surgery. All procedures were conducted by the same group of experienced neurotologists.In a tertiary neurotologic private practice (...) , the percentage of 1,023 patients with delayed facial paresis after undergoing microsurgical removal of unilateral acoustic tumor with no preoperative treatment was compared to the percentage of 530 patients with preoperative famciclovir treatment. Patients were prescribed famciclovir 500 mg BID for 3 days before surgery and 5 days postoperative. The House-Brackmann Facial Nerve Grade was assessed prospectively at preoperative, immediate postoperative, and discharge from the hospital in both groups.Twenty

2008 Laryngoscope

355. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. (PubMed)

liver transplant patients and 18 heart transplant recipients were retrospectively analysed. Patients had been treated with famciclovir and/or lamivudine, in addition some had also received adefovir in cases of lamivudine resistance. Quantitative HBsAg and hepatitis B virus e antigen (HBeAg) levels were determined with the Architect assay. HBV DNA levels were determined with different assays available at given time points.We did not find a significant correlation between either HBsAg or HBeAg and HBV

2008 Antiviral Therapy

356. Famciclovir substitution for patients with acyclovir-associated renal toxicity. (PubMed)

Famciclovir substitution for patients with acyclovir-associated renal toxicity. Acyclovir-induced nephrotoxicity is well known, but published literature lacks information on the safety of substitution with other antiviral agents. We describe four patients with acyclovir-induced renal toxicity that were subsequently managed with hydration and famciclovir. All four patients subsequently had improvements in their symptoms with full recovery of their baseline renal function.

2008 Journal of Infection

357. Herpes zoster antivirals and pain management. (PubMed)

searching by pertinent topics, authors, and journals.If started within 72 hours of the onset of the acute HZ rash, the oral antiviral agents acyclovir, valacyclovir, and famciclovir significantly shorten the periods of acute pain, virus shedding, rash, acute and late-onset anterior segment complications, and, in the case of valacyclovir and famciclovir, the incidence and severity of PHN. However, these medications do not prevent PHN, which remains a common and debilitating complication of HZ in older

2008 Ophthalmology

358. Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

of the investigator puts the subject at potential risk from study participation or makes adherence to the study protocol unlikely. Receipt of the following drugs with anti-HBV activity within 90 days prior to study entry or anticipated receipt during the course of the study including: adefovir(ADV), telbivudine, alpha interferon, penciclovir (Denavir) (except if given for < 4 weeks), famciclovir (Famvir), diaminopurine dioxolane (DAPD), clevudine (L-FMAU), thymosin alpha 1, ganciclovir (treatment limited to < 7

2008 Clinical Trials

359. Live, attenuated varicella zoster vaccination of an immunocompromised patient. (PubMed)

), a diagnosis of disseminated cutaneous herpes zoster was made. The patient was treated successfully with a course of famciclovir for 10 days and cephalexin for 7 days for a secondary bacterial infection. A review of the medical literature disclosed no reports of Zostavax given to adult cancer patients immunocompromised by systemic chemotherapy. Therefore, we believe this report is the first to describe the consequences of Zostavax administration to such a host. Clinicians should take care to review

Full Text available with Trip Pro

2008 Journal of General Internal Medicine

360. The treatment of herpes simplex infections: an evidence-based review. (PubMed)

The treatment of herpes simplex infections: an evidence-based review. Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research

Full Text available with Trip Pro

2008 Archives of Internal Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>